ResearcherUPMC Hillman Cancer CenterNo recent work listed
Rodney E. Wegner
Matched on ORCID iD 0000-0003-2416-3499; OpenAlex author ID A5078734526. Sources: OpenAlex.
Their work
- Papers
- 7 (first author 0, last author 2)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 32
2013: 2 papers · 2014: none · 2015: none · 2016: none · 2017: none · 2018: 1 paper · 2019: 3 papers · 2020: none · 2021: none · 2022: 1 paper
Papers 7
- Concepts and Outcomes of Perioperative Therapy in Stage IA-III Pancreatic Cancer-A Cross-Validation of the National Cancer Database (NCDB) and the German Cance… Last author DOI 10.3390/cancers14040868↗
- Time to Adjuvant Systemic Therapy Following Pancreatic Cancer Resection and Effect on Outcome. Last author DOI 10.1097/mpa.0000000000001373↗
- Long-term outcomes by response to neoadjuvant chemotherapy or chemoradiation in patients with resected pancreatic adenocarcinoma. Co-author DOI 10.21037/jgo.2019.07.02↗
- Incidence and risk factors for post-operative mortality, hospitalization, and readmission rates following pancreatic cancer resection. Co-author DOI 10.21037/jgo.2019.09.01↗
- Results of a prospective phase 2 clinical trial of induction gemcitabine/capecitabine followed by stereotactic ablative radiation therapy in borderline resecta… Co-author DOI 10.1016/j.prro.2017.10.001↗
- Stereotactic body radiotherapy in the treatment of pancreatic adenocarcinoma in elderly patients. Co-author DOI 10.1186/1748-717x-8-240↗
- Pathologic response with neoadjuvant chemotherapy and stereotactic body radiotherapy for borderline resectable and locally-advanced pancreatic cancer. Co-author DOI 10.1186/1748-717x-8-254↗
Closest collaborators
The 25 strongest of 32 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Alexander V. Kirichenko · 3 shared papers, 2019–2022 · strength 0.29
- Paper Concepts and Outcomes of Perioperative Therapy in Stage IA-III Pancreatic Cancer-A Cross-Validation of the National Can… DOI 10.3390/cancers14040868↗
- Paper Time to Adjuvant Systemic Therapy Following Pancreatic Cancer Resection and Effect on Outcome. DOI 10.1097/mpa.0000000000001373↗
- Paper Incidence and risk factors for post-operative mortality, hospitalization, and readmission rates following pancreatic ca… DOI 10.21037/jgo.2019.09.01↗
- Dulabh Kaur Monga · 3 shared papers, 2019 · strength 0.28
- Paper Long-term outcomes by response to neoadjuvant chemotherapy or chemoradiation in patients with resected pancreatic adeno… DOI 10.21037/jgo.2019.07.02↗
- Paper Time to Adjuvant Systemic Therapy Following Pancreatic Cancer Resection and Effect on Outcome. DOI 10.1097/mpa.0000000000001373↗
- Paper Incidence and risk factors for post-operative mortality, hospitalization, and readmission rates following pancreatic ca… DOI 10.21037/jgo.2019.09.01↗
- Vivek Verma · 2 shared papers, 2019 · strength 0.19
- Paper Long-term outcomes by response to neoadjuvant chemotherapy or chemoradiation in patients with resected pancreatic adeno… DOI 10.21037/jgo.2019.07.02↗
- Paper Incidence and risk factors for post-operative mortality, hospitalization, and readmission rates following pancreatic ca… DOI 10.21037/jgo.2019.09.01↗
- Suzanne Schiffman · 2 shared papers, 2019 · strength 0.18
- Shyam J Thakkar · 2 shared papers, 2019 · strength 0.18
- Steven A. Burton · 3 shared papers, 2013–2018 · strength 0.15
- Paper Results of a prospective phase 2 clinical trial of induction gemcitabine/capecitabine followed by stereotactic ablative… DOI 10.1016/j.prro.2017.10.001↗
- Paper Stereotactic body radiotherapy in the treatment of pancreatic adenocarcinoma in elderly patients. DOI 10.1186/1748-717x-8-240↗
- Paper Pathologic response with neoadjuvant chemotherapy and stereotactic body radiotherapy for borderline resectable and loca… DOI 10.1186/1748-717x-8-254↗
- Dwight Earl Heron · 3 shared papers, 2013–2018 · strength 0.15
- Paper Results of a prospective phase 2 clinical trial of induction gemcitabine/capecitabine followed by stereotactic ablative… DOI 10.1016/j.prro.2017.10.001↗
- Paper Stereotactic body radiotherapy in the treatment of pancreatic adenocarcinoma in elderly patients. DOI 10.1186/1748-717x-8-240↗
- Paper Pathologic response with neoadjuvant chemotherapy and stereotactic body radiotherapy for borderline resectable and loca… DOI 10.1186/1748-717x-8-254↗
- Herbert J. Zeh · 3 shared papers, 2013–2018 · strength 0.15
- Paper Results of a prospective phase 2 clinical trial of induction gemcitabine/capecitabine followed by stereotactic ablative… DOI 10.1016/j.prro.2017.10.001↗
- Paper Stereotactic body radiotherapy in the treatment of pancreatic adenocarcinoma in elderly patients. DOI 10.1186/1748-717x-8-240↗
- Paper Pathologic response with neoadjuvant chemotherapy and stereotactic body radiotherapy for borderline resectable and loca… DOI 10.1186/1748-717x-8-254↗
- Carlos Fernández-del Castillo · 1 shared paper, 2022 · strength 0.11
- Tobias Keck · 1 shared paper, 2022 · strength 0.11
- Ekaterina Petrova · 1 shared paper, 2022 · strength 0.11
- Taisuke Baba · 1 shared paper, 2022 · strength 0.11
- Hryhoriy V. Lapshyn · 1 shared paper, 2022 · strength 0.11
- Louisa Bolm · 1 shared paper, 2022 · strength 0.11
- Rüdiger Braun · 1 shared paper, 2022 · strength 0.11
- Kim C. Honselmann · 1 shared paper, 2022 · strength 0.11
- Hiroki Sato · 1 shared paper, 2022 · strength 0.11
- Ulrich Friedrich Wellner · 1 shared paper, 2022 · strength 0.11
- Natalie Petruch · 1 shared paper, 2022 · strength 0.11
- Jon Michael Harrison · 1 shared paper, 2022 · strength 0.11
- Dirk Rades · 1 shared paper, 2022 · strength 0.11
- Nathan Bahary · 2 shared papers, 2013–2018 · strength 0.11
- Paper Results of a prospective phase 2 clinical trial of induction gemcitabine/capecitabine followed by stereotactic ablative… DOI 10.1016/j.prro.2017.10.001↗
- Paper Pathologic response with neoadjuvant chemotherapy and stereotactic body radiotherapy for borderline resectable and loca… DOI 10.1186/1748-717x-8-254↗
- Ahmed Khattab · 1 shared paper, 2019 · strength 0.10
- Ethan Bernard Ludmir · 1 shared paper, 2019 · strength 0.10
- Richard J. White · 1 shared paper, 2019 · strength 0.09
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.